Zentalis Pharmaceuticals: Pay

Zentalis Pharmaceuticals paid its 5 named executives $7.0M in total in FY2025 (Dec). CEO Julie Eastland was paid $1.3M of that.

Pay$100 in the stock at the end of FY23 → $9
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Andrea PaulFormer Chief Legal Officer and Corporate Secretary
FY2025 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
2 years
Julie EastlandPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Mark Lackner, Ph.D.Former Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Ingmar Bruns, M.D.Chief Medical Officer
FY2025 (Dec)
1 year
James BucherChief Legal Officer and Corporate Secretary
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2023 (Dec), the median CEO pay of the 15 peers with pay on file was $7.9M. CEO pay of Zentalis Pharmaceuticals for that year is not on file.

  1. 1Relay Therapeutics
  2. 2Allogene Therapeutics
  3. 3CRISPR Therapeutics AG
  4. 4Arcus Biosciences
  5. 5Kymera Therapeutics
  6. 6Cytokinetics
  7. 7Celldex Therapeutics
  8. 8Denali Therapeutics
  9. 9Arvinas
  10. 10Beam Therapeutics
  11. 11Kura Oncology
  12. 12C4 Therapeutics
  13. 13Fate Therapeutics
  14. 14Nektar Therapeutics
  15. 15Lyell Immunopharma
  16. 16Zentalis PharmaceuticalsNot disclosed
  17. 17Day One Biopharmaceuticals, Inc.Not disclosed
  18. 18ErascaNot disclosed
  19. 19ImmunoGen, Inc.Not disclosed
  20. 20Merus N.V.Not disclosed
  21. 21Mirati Therapeutics, Inc.Not disclosed
  22. 22Sana BiotechnologyNot disclosed
  23. 23Springworks Therapeutics, Inc.Not disclosed
  24. 24TG TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.